Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03509974
Other study ID # CAM5706
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 18, 2018
Est. completion date March 19, 2020

Study information

Verified date October 2021
Source Cochlear
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study the initial experience with implanting and fitting a new Bone Conduction system in pediatric patient population with conductive, mixed or single-sided deafness.


Description:

Experimental: Bone-conduction hearing device The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet. Device: Osia System An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date March 19, 2020
Est. primary completion date February 20, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 18 Years
Eligibility Inclusion Criteria: Individuals 5 through 18 years of age will be eligible for inclusion in the investigation if all of the criteria below are met: Conductive or mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure-tone average (PTA4; mean of 0.5, 1, 2, and 4 kHz) of less than or equal to 55 dB HL. Subject does not benefit from or will not wear a conventional hearing aid. Note: Candidates may include individuals seeking new implantation unilaterally (in one ear) or bilaterally (both ears) as well as individuals already implanted with a bone-anchored device seeking a second-side implant. OR Single-sided sensorineural deafness who is a candidate for Baha surgery. Air conduction thresholds with a pure-tone average (PTA4; mean of 0.5, 1, 2, and 3 kHz) of less that equal to 20 dB HL in the good ear. Subject does not benefit from or will not wear a conventional hearing aid Exclusion Criteria: Uncontrolled diabetes as judged by the investigator. Subject who has received radiotherapy in the area of implantation, or such radiotherapy is planned during the study period. Current use of ototoxic drugs. Condition that could jeopardize osseointegration and/or wound healing or condition that may have an impact on the outcome of the investigation as judged by the investigator. Insufficient bone quality and quantity for implantation of a BI300 Implant, as determined by the surgeon. Unable to follow investigational procedures. Participation in another clinical investigation with pharmaceutical and/or device

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Osseointegrated Steady State Implant
Bone anchored, bone conduction hearing system

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Cochlear

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting Type and Severity of Adverse Events in the Pediatric Population Implanted With the Osia System Number, Type and Severity of Adverse Events will be tabulated and summarized. Surgery to 12 months post-operative